Trials / Completed
CompletedNCT02061709
Evaluating the Efficacy of Ragweed-SPIRE Following Exposure to Ragweed Allergen in an Environmental Exposure Chamber
A Double-Blind, Randomised, Placebo-Controlled Study to Evaluate Three Dose Regimens of Ragweed-SPIRE in Ragweed Allergic Subjects Following Challenge With Ragweed Allergen in an Environmental Exposure Chamber
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 280 (actual)
- Sponsor
- Circassia Limited · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether Ragweed-SPIRE is safe and effective at reducing allergy symptoms in people who suffer from allergy to Ragweed pollen
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Ragweed-SPIRE | |
| BIOLOGICAL | Placebo |
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2014-10-01
- Completion
- 2014-10-01
- First posted
- 2014-02-13
- Last updated
- 2015-03-20
Locations
5 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT02061709. Inclusion in this directory is not an endorsement.